BioCardia files revised Helix De Novo submission to FDA
BioCardia completed a revised pre-submission for its Helix Catheter based on FDA guidance, aiming for approval as a unique therapeutic delivery device. This clearance could significantly expand partnership opportunities in cardiology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed